Equities Analysts Set Expectations for CRDL FY2025 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Research analysts at Brookline Cap M issued their FY2025 EPS estimates for shares of Cardiol Therapeutics in a note issued to investors on Tuesday, February 3rd. Brookline Cap M analyst F. Ahmed forecasts that the company will post earnings of ($0.30) per share for the year. Brookline Cap M currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Brookline Cap M also issued estimates for Cardiol Therapeutics’ Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.29) EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its earnings results on Thursday, November 13th. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09).

A number of other brokerages have also recently weighed in on CRDL. Brookline Capital Acquisition raised shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Cardiol Therapeutics in a report on Monday, December 1st. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $9.00.

Cardiol Therapeutics Trading Up 3.6%

Shares of NASDAQ CRDL traded up $0.03 during midday trading on Friday, hitting $0.99. The stock had a trading volume of 174,245 shares, compared to its average volume of 346,622. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.01. Cardiol Therapeutics has a 1-year low of $0.77 and a 1-year high of $1.59. The company has a market capitalization of $111.10 million, a price-to-earnings ratio of -3.32 and a beta of 1.04. The company has a fifty day moving average price of $1.00 and a 200 day moving average price of $1.09.

Institutional Investors Weigh In On Cardiol Therapeutics

A number of institutional investors have recently modified their holdings of CRDL. Tejara Capital Ltd increased its holdings in Cardiol Therapeutics by 2.2% in the second quarter. Tejara Capital Ltd now owns 3,265,819 shares of the company’s stock valued at $4,442,000 after buying an additional 70,829 shares during the last quarter. Thompson Davis & CO. Inc. bought a new stake in shares of Cardiol Therapeutics in the 2nd quarter valued at approximately $39,000. Susquehanna International Group LLP raised its position in shares of Cardiol Therapeutics by 366.5% during the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock valued at $100,000 after acquiring an additional 73,375 shares in the last quarter. Citadel Advisors LLC boosted its holdings in Cardiol Therapeutics by 1,132.6% in the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock worth $496,000 after purchasing an additional 425,862 shares during the period. Finally, Bank of America Corp DE increased its stake in Cardiol Therapeutics by 1,983.0% during the third quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock valued at $590,000 after purchasing an additional 524,598 shares during the last quarter. Institutional investors and hedge funds own 12.49% of the company’s stock.

Trending Headlines about Cardiol Therapeutics

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CRDL to a “Strong‑Buy,” highlighting bullish analyst sentiment that can spur buying interest from investors and funds. Zacks Upgrade
• Positive Sentiment: Brookline published detailed EPS estimates for 2025–2026 (quarterly losses around $0.07–$0.08; FY2026 forecast ≈ ($0.29)), which are modestly less negative than the consensus FY2026 estimate of ($0.33). The slightly improved outlook vs. consensus can be read as a relative improvement in near‑term expectations. Brookline Estimates
• Neutral Sentiment: Published short‑interest data claims a “large increase” but simultaneously reports 0 shares short and NaN changes, with a days‑to‑cover of 0.0 — the figures look inconsistent and are unlikely to be a meaningful market driver until clarified by reliable data.
• Negative Sentiment: Brookline’s forecasts still show recurring quarterly losses and a negative FY outlook (company remains unprofitable). Ongoing losses limit valuation upside and mean the stock remains sensitive to funding, clinical, or regulatory news. Brookline Estimates

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.